Lung cancer patients harboring therapeutically actionable fusion genes, such as ALK, RET, and ROS1, have experienced clinical benefits owing to the development of effective targeted therapies with crizotinib being foremost (Chao et al., 2012; Shaw et al., 2014; Solomon et al., 2014). Here, RET is linked to lung carcinoma.